User:Mr. Ibrahem/Etelcalcetide

Etelcalcetide, sold under the brand name Parsabiv, is a medication used to treat secondary hyperparathyroidism in people undergoing hemodialysis. It is unclear if it changes outcomes such as life expectancy and heart disease. It is given by injection into a vein at the end of each dialysis session.

Common side effects include low calcium, muscle spasms, diarrhea, and nausea. Other side effects may include allergic reactions, heart failure, upper GI bleeding, and adynamic bone disease. It is a calcimimetic and works by activating calcium-sensing receptors in the parathyroid gland.

Etelcalcetide was approved for medical use in Europe in 2016 and the United States in 2017. In the United Kingdom a dose of 5 mg three times per week costs the NHS about £330 for 4 weeks as of 2021. In the United States this amount costs about 2,100 USD.